Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Multiple myeloma represents the second most common hematological malignancy.VELCADE is a small molecule to treat human malignancies. Its anti-neoplastic effect invovles several distinct mechanisms including inhibition of cell growth. Patients who have relapsed or are refractory to therapy, the standard of care is now VELCADE based on the results of previous clinical trials.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Voluntary written informed consent with the understanding that the consent may be w/d by the patient at any time w/o prejudice to future medical care.
Patient previously diagnosed with Multiple Myeloma (MM).
Patient previously tolerated 0.7, 1.0, or 1.3 mg/m2/dose of VELCADE alone or therapy combination and had at least a greater/equal 50% reduction in M-Protein upon completion of VELCADE therapy. The DOR prior to VELCADE greater/equal 4 months for the patient population.
It has been greater/equal 2 months since the patient's last VELCADE dose and the patient meets certain Lab criteria as per protocol.
Patient has a Karnosfsky performance status greater/equal 60%.
Patient has a life-expectancy greater than 3 months.
Patient has laboratory values (defined in protocol) within 14 days before enrollment.
Patients with a Hx of PD, minimal response, or stable disease (SD)on first exposure to VELCADE.
Patient has received chemotherapy, radiotherapy, immunotherapy or experimental therapy to treat multiple myeloma since their last dose of VELCADE.
Patients who achieved a CR or PR but relapsed while on therapy.
Patient had major surgery w/in 2 wks before enrollment.
Patient has a Hx of allergic reaction to compounds containing boron or mannitol.
Patient has peripheral sensory neuropathy of Grade 2 w/pain or greater intensity.
Patient has cardiac amyloidosis.
Patient has poorly controlled hypertension, diabetes mellitus, or other serious medical or pysychiatric illness.
Patient is known to be human immunodeficiency virus (HIV)+.
Patient is known to be hepatitis B surface antigen-positive or has known active hepatitis C infection.
Patient has an active systemic infection requiring treatment.
Female patient is pregnant or breast-feeding. Confirmation must be established by a negative serum B-hCG.
Patient is currently enrolled in another clinical research study.